TGFB1 and pancreatic neoplasm: Further studies addressing the effects of targeting TGF-β signalling by galunisertib in macrophages and Treg cells, and the consequent potential modulation of the immunosuppressive tumour microenvironment and chemoresistance in pancreatic cancer are warranted.